

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
21 July 2022 (21.07.2022)



(10) International Publication Number
WO 2022/153250 A1

(51) International Patent Classification:

A61K 38/13 (2006.01) C07K 7/64 (2006.01)
A61P 37/06 (2006.01) G01N 33/48 (2006.01)
A61P 39/00 (2006.01)

(21) International Application Number:

PCT/IB2022/050316

(22) International Filing Date:

14 January 2022 (14.01.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/138,325 15 January 2021 (15.01.2021) US
63/245,779 17 September 2021 (17.09.2021) US
63/246,765 21 September 2021 (21.09.2021) US

(71) Applicant: AURINIA PHARMACEUTICALS INC.

[CA/CA]; 1203 - 4464 Markham Street, Victoria, British
Columbia V8Z 7X8 (CA).

(72) Inventors: MARTIN, Michael; 1203 - 4464 Markham
Street, Victoria, British Columbia V8Z 7X8 (CA).
HUIZINGA, Robert B.; 1203 - 4464 Markham Street,
Victoria, British Columbia V8Z 7X8 (CA). SOLOMONS,
Neil; 1203 - 4464 Markham Street, Victoria, British Colum-
bia V8Z 7X8 (CA).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,

(54) Title: PROTOCOL TO MINIMIZE CALCINEURIN INHIBITOR NEPHROTOXICITY




FIG. 6

(57) Abstract: Provided herein are methods of employing pharmacodynamics regimens to maximize effectiveness of voclosporin in treatment of proteinuric kidney diseases while minimizing undesirable side effects, such as but not limited to calcineurin inhibitor nephrotoxicity. Also provided are methods of assessments of renal functions and/or conditions, and corresponding protocols to modify, stop, restore and/or re-initiate voclosporin dosing and administrations to maximize effectiveness of voclosporin in treatment of proteinuric kidney diseases while minimizing undesirable side effects.

[Continued on next page]

UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*